NYBC Ventures

Based on our deep science and focused on patients in need.

Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Functional Fluidics Inc. is a company that develops biomarkers and surrogate endpoints for evaluating thrombosis and adhesion formation in whole blood, particularly in the context of sickle cell disease. Founded in 2014 and headquartered in Detroit, Michigan, the company specializes in standardizing clinical blood function assays to assess individual patient responses, focusing on red blood cell health. Functional Fluidics offers a range of proprietary assays that include flow adhesion, mechanical fragility, and adhesion characterization. Additionally, the company provides contract research services, which encompass initial consultation, preclinical validation, patient selection, monitoring, and companion diagnostic development. These services are designed to assist pharmaceutical, biotech, and academic research organizations in improving patient care by providing objective data on red blood cell health.

ViTToria Biotherapeutics specializes in developing gene-edited cell therapies, focusing on next-generation T-cell therapeutics that aim to address significant unmet medical needs. The company’s proprietary Senza5 Technology enhances the efficacy, safety, and utility of these cell-based treatments in preclinical settings. By improving dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing the time from production to patient administration, ViTToria Biotherapeutics enables healthcare providers to achieve better patient outcomes. The innovative approach of the company positions it as a leader in the evolving field of cell therapies.

Aronora is a biotechnology company focused on the early-stage commercial development of proprietary biologic therapeutics, specifically targeting blood clotting diseases. The company is developing next-generation therapeutics, including recombinant monoclonal antibodies and enzymes, aimed at preventing pathological thrombi while preserving hemostasis. This innovative approach seeks to address the limitations of existing clot-busting and blood-thinning drugs, tackling a leading cause of death worldwide. Through its advanced therapeutics, Aronora aims to provide effective solutions that could potentially save thousands of lives each year.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify diseases that share common biological characteristics and create novel therapeutics that can effectively treat multiple conditions with a single treatment. This approach not only addresses the needs of patients suffering from rare diseases but also presents a unique opportunity for pharmaceutical companies to broaden their therapeutic offerings within a streamlined pipeline. By concentrating on life-changing therapies, Star Therapeutics aspires to make a significant impact on the lives of millions of patients.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

HealthQuest Capital is a growth equity firm based in Redwood City, California, established in 2013. The firm specializes in investing in commercial-stage companies across various sectors of the healthcare industry, including medical devices, biopharmaceuticals, healthcare services, and healthcare information technology. HealthQuest Capital focuses on innovative companies that develop medical technologies, diagnostics, research tools, and digital health solutions, aiming to support advancements that improve healthcare delivery and outcomes. As a Registered Investment Adviser, the firm is committed to fostering growth in the healthcare sector through strategic investments.

KaloCyte, Inc. is a pre-clinical stage healthcare biotech company based in Baltimore, Maryland, founded in 2016. The company focuses on developing ErythroMer, a dried and bio-inspired artificial red blood cell intended to address life-threatening blood loss in situations where stored red blood cells are either unavailable or unsuitable for use. ErythroMer aims to provide context-dependent oxygen delivery while minimizing complications such as vasoconstriction and methemoglobin formation. This innovative approach seeks to enhance trauma care services by offering an effective alternative for managing traumatic hemorrhage when traditional blood supplies are inadequate.

STRM.BIO is a biotechnology company focused on enhancing gene therapy delivery through the use of extracellular vesicles (EVs). These natural carriers, which transport nucleic acids and proteins, offer innate targeting capabilities and can be mass-produced efficiently. By leveraging EVs, STRM.BIO aims to create a new class of therapeutics that not only introduces novel treatments but also improves the effectiveness of existing therapies. The company's approach seeks to simplify and enhance the safety of gene therapy delivery directly to patients, fulfilling the potential of this innovative medical field.

Catena Biosciences is a biotechnology company focused on advancing protein conjugation technology to develop novel therapeutics for autoimmune disorders, oncology, and vaccine development. The company specializes in the efficient and selective attachment of proteins using natural amino acids, specifically tyrosine and cysteine. This innovative approach allows researchers to create biologic structures more rapidly than traditional methods, enhancing the potential for medical research and treatment options in various disease areas. Catena Biosciences aims to contribute significantly to the field of biomedicine through its cutting-edge technology and applications.

Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease.

Vega Therapeutics is a biotechnology startup that is in the clinical stages of developing innovative treatments for rare blood disorders. The company focuses on addressing unmet needs in this area by creating novel, first-in-class therapies. Its research centers on a unique mechanism of action that targets Protein S, aiming to provide effective hemostatic therapies for patients suffering from various bleeding disorders. Through its dedicated approach, Vega Therapeutics seeks to improve treatment options for individuals affected by these uncommon conditions.